PULMONARY MUCOEPIDERMOID CARCINOMA: DIAGNOSIS AND TREATMENT
Abstract
Pulmonary mucoepidermoid carcinoma (MEC) is a rare malignant neoplasm with the clinical picture mimicking infectious aetiologies in most of the patients. Hence, this rare entity poses a great challenge to the pathologist in terms of diagnosis and to the oncologist in terms of treatment. This case report aims to look at the clinicopathological features of pulmonary MEC, the role of immunohistochemical analysis in diagnosis and choice of chemotherapeutic agent. The objective of reporting this case on MEC is not only the rare frequency of this carcinoma but also to highlight the importance of adequate immunohistochemical analysis in establishing the diagnosis.
Key words: Lung cancer, mucoepidermoid carcinoma, chemotherapy
References
Shen C, Che G. Clinicopathological analysis of pulmonary mucoepidermoid carcinoma. World J Surg Oncol 2014;12:33.
Kitada M, Matsuda Y, Sato K, et al. Mucoepidermoid carcinoma of the lung: A case report. J Cardiothorac Surg 2011;6:132.
Alsidawi S, Morris JC, Wikenheiser-Brokamp KA, et al. Mucoepidermoid carcinoma of the lung: A case report and literature review. Case Rep Oncol Med 2013;2013:625243.
Liu X, Adams AL. Mucoepidermoid carcinoma of the bronchus: A review. Arch Pathol Lab Med 2007;131:1400-4.
Chopra A, Shim C, Sharma N, et al. Primary salivary type lung tumor: Mucoepidermoid carcinoma. Respir Med Case Rep 2013;9:18-20.
Kuzucuoglu M, Karamustafaoglu YA, Cicin I, et al. A rarely seen mucoepidermoid carcinoma of the left main bronchus. J Cancer Res Ther 2014;10:384-6.
Belgod SR, Reddy RH, Kumar SP. Mucoepidermoid carcinoma of the lung: A rare entity. Oxf Med Case Reports 2015; 2015:203-5.
Xi JJ, Jiang W, Lu SH, et al. Primary pulmonary mucoepidermoid carcinoma: An analysis of 21 cases. World J Surg Oncol 2012;10:232.
Han SW, Kim HP, Jeon YK, et al. Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. Lung Cancer 2008;61:30-4.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.
